INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 454m ago
HOUSE PTR54m ago
SEC 13F54m ago
ROBINHOOD CHAIN54m ago
CR
Corporate insider

Cline Christopher R.

CHIEF FINANCIAL OFFICERCIK 0001943192

EDGAR filingsOpen in network
Disclosed transactions18
Buys / sells0 / 12
Max Insider Score26
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.70M
27.5K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Travere Therapeutics, Inc.CHIEF FINANCIAL OFFICER · Feb 5, 2026
8
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$26K
400 sh
Sep 15, 2026
Sep 17, 2026
traded Sep 15, 2026
+2d
SEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
20.0K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

21
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.30M
20.7K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

11
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$121K
1,900 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

2
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$349K
20.0K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

16
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$102K
2,181 sh
May 5, 2026May 6, 2026
traded May 5, 2026
+1dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award · 10b5-1 plan
A—
8,500 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

13
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$14K
310 sh
May 6, 2026May 6, 2026
traded May 6, 2026
+0dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award · 10b5-1 plan
A—
14.0K sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

16
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$370
9 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

26
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$304K
7,239 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

16
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1,875
65 sh
Apr 13, 2026Apr 15, 2026
traded Apr 13, 2026
+2dSEC FORM 4

Evidence

16
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$43K
1,014 sh
Apr 15, 2026Apr 15, 2026
traded Apr 15, 2026
+0dSEC FORM 4

Evidence

18
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$53K
1,635 sh
Feb 4, 2026Feb 5, 2026
traded Feb 4, 2026
+1dSEC FORM 4

Evidence

15
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$3,619
110 sh
Feb 4, 2026Feb 5, 2026
traded Feb 4, 2026
+1dSEC FORM 4

Evidence